The recently concluded session had traders exchanging Cymabay Therapeutics, Inc. (NASDAQ:CBAY) high level. Roughly 0.76 million shares changed hands compared to the three-month volume average 0.73 million shares. The first trade took place at $8.53 and the stock went down -4.14% to attain the closing price of $8.22.Cymabay Therapeutics, Inc. (CBAY) Analyst Opinion
Cymabay Therapeutics, Inc. has a consensus outperform rating from 6 Wall Street analysts, and the number of shares currently sold short amount to at least 5.82% of shares outstanding. The stock sank -4.59% last month and is up 374.86 this year. Wall Street is only getting more bullish on the stock, with 6 of analysts who cover CBAY having a buy-equivalent rating. Analysts have placed a $14.5 price target on Cymabay Therapeutics, Inc., suggesting a 76.4% gain from recent close. It’s currently trading about -12.61% below its 52-week high.Cymabay Therapeutics, Inc. (NASDAQ:CBAY) Intraday View
This stock (CBAY) is ahead of its 52-week low with 462.67%. Its last month’s stock price volatility remained 6.78% which for the week stands at 6.06%. The share price has moved backward from its 20 days moving average, trading at a distance of -4.33% and stays -3.29% away from its 50 days moving average. Over the last five days, shares have faced -2.67% losses and now is up 37.76% since hitting its 200-day moving average of $6.942. Cymabay Therapeutics, Inc. (CBAY) has made its way to a 12-month gain of 330.1%.
Turning to Keane Group, Inc. (NYSE:FRAC), its shares were trading at $13.89 a retreat of $-0.6, on the trading floor. The stock, after opening at $14.32, touched a high of $14.66 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2.1. Keane Group, Inc. has 4 buy ratings, 6 holds and 0 sells even after the stock tumbled -39.42% from its high of $22.93 to a $1.55 billion market value through last close.
The company’s consensus rating on Reuter’s scale slipped from 2.19 to 2.13 during a month. Analysts set a 12-month price target of $20.12 a share. The target implies a 44.85% spike from where the shares are currently trading. Also, the current price highlights a discount of 101.58% to analysts’ high consensus price target.Keane Group, Inc. (NYSE:FRAC) Intraday Trading
The counter witnessed a trading volume of 1.4 million shares versus an average volume of 0.73 million shares during last trading session. Its last month’s stock price volatility remained 5.57% which for the week approaches 4.49%. The lowest price the stock reached in the last trading day was $13.81 and compares with the $12.42 52-week low. The stock recovered 11.84% since its low point and has performed -35.84% year-to-date.